Inflammatory bowel disease (IBD) takes a toll on your health; not only on your digestive system but also on your entire body. However, that’s only part of the story: Crohn’s disease and ulcerative colitis also eat away at your professional and personal relationships, as well as your finances. IBD is expensive. Having outstanding medical bills can put significant stress into the life of someone with IBD. In some cases, medical debt can make it difficult to be seen by providers because it’s not possible to make an appointment or get a test until a bill is paid.
That’s why people in the chronic illness community are always on the lookout for ways to maximize costs or to use lower-cost services whenever possible. Unfortunately, it can take time and energy to find free or low-cost services; and people with IBD may not have these resources available to them, either. The resources found here can be used to help keep costs a little lower, while still accessing the services that people with IBD need. Continue reading
“Can you see anything?” asked Lord Carnarvon.
“Yes, wonderful things,” replied Howard Carter, upon seeing King Tutankhamun’s tomb for the first time
On February 26, 2016, I attended an event at the Janssen Biotech facilities in Pennsylvania called The BioExperience. (Janssen is the company that makes IBD medication Remicade.) BioExperience. It sounds like a ride at Disney Epcot: exciting and full of potential. And actually it really was just that. Exciting and informative and something that I would never get anywhere else. I want to tell you a little about what this event was all about.
Aww, the poor mice. Mice studies are important because they are a first step. But they’re just that — preliminary results that may or may not lead to something meaningful for patients.
I often make a joke that when I see a study done on mice or rats my eyes glaze over and I move on. I don’t, really, of course. I read them and will watch future research to see how things pan out, and if more study moves the knowledge further and leads to anything significant.
However, I don’t usually write up a summary or include it in an article as a reference. This is because I’ve learned that most people aren’t interested in reading about mice studies.
The other reason that I don’t often report on them is because they often don’t lead to anything. The mainstream media, however, often gloms on to these stories as if they’re going to change everything for patients. But they don’t, at least, they won’t for a long time. Continue reading